Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1981 2
1982 3
1983 9
1984 12
1985 11
1986 18
1987 31
1988 42
1989 65
1990 66
1991 60
1992 57
1993 64
1994 76
1995 49
1996 71
1997 50
1998 56
1999 55
2000 70
2001 58
2002 74
2003 63
2004 44
2005 66
2006 61
2007 68
2008 63
2009 72
2010 62
2011 59
2012 62
2013 77
2014 53
2015 69
2016 51
2017 35
2018 44
2019 45
2020 39
2021 38
2022 38
2023 41
2024 16

Text availability

Article attribute

Article type

Publication date

Search Results

2,027 results

Results by year

Filters applied: . Clear all
Page 1
Goserelin.
[No authors listed] [No authors listed] 2023 May 28. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2023 May 28. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31644049 Free Books & Documents. Review.
Goserelin is a parenterally administered, gonadotropin releasing hormone (GnRH) agonist which causes an inhibition of estrogen and androgen production and is used predominantly to treat prostate cancer. Goserelin has been associated with a modest rate of serum enzym …
Goserelin is a parenterally administered, gonadotropin releasing hormone (GnRH) agonist which causes an inhibition of estrogen and an …
Effectiveness of three different luteinizing hormone-releasing hormone agonists in the chemical castration of patients with prostate cancer: Goserelin versus triptorelin versus leuprolide.
Shim M, Bang WJ, Oh CY, Lee YS, Cho JS. Shim M, et al. Investig Clin Urol. 2019 Jul;60(4):244-250. doi: 10.4111/icu.2019.60.4.244. Epub 2019 May 21. Investig Clin Urol. 2019. PMID: 31294133 Free PMC article.
Changes in testosterone concentration during 9 months of ADT with goserelin 11.34 mg, triptorelin 11.25 mg, and leuprolide 11.25 mg were analyzed using a mixed model. ...The lowest mean testosterone levels during 9 months of treatment were achieved in patients treated with …
Changes in testosterone concentration during 9 months of ADT with goserelin 11.34 mg, triptorelin 11.25 mg, and leuprolide 11.25 mg w …
Goserelin ('Zoladex')--offering patients more choice in early breast cancer.
Mitchell H. Mitchell H. Eur J Oncol Nurs. 2004;8 Suppl 2:S95-103. doi: 10.1016/j.ejon.2004.09.004. Eur J Oncol Nurs. 2004. PMID: 15590321 Review.
The luteinising hormone-releasing hormone analogue goserelin ('Zoladex') suppresses ovarian oestrogen production in pre- and perimenopausal women. Goserelin is a biodegradable, sustained-release 3.6 mg depot that is administered by subcutaneous injection every 28 da …
The luteinising hormone-releasing hormone analogue goserelin ('Zoladex') suppresses ovarian oestrogen production in pre- and perimeno …
Clinical pharmacokinetics of goserelin.
Cockshott ID. Cockshott ID. Clin Pharmacokinet. 2000 Jul;39(1):27-48. doi: 10.2165/00003088-200039010-00003. Clin Pharmacokinet. 2000. PMID: 10926349 Review.
Goserelin is a synthetic decapeptide analogue of luteinising hormone-releasing hormone (LHRH). ...There is no clinically relevant accumulation of goserelin during multiple administration of these depots. Goserelin is extensively metabolised prior to excretion …
Goserelin is a synthetic decapeptide analogue of luteinising hormone-releasing hormone (LHRH). ...There is no clinically relevant acc …
Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in benign gynaecological disorders.
Perry CM, Brogden RN. Perry CM, et al. Drugs. 1996 Feb;51(2):319-46. doi: 10.2165/00003495-199651020-00009. Drugs. 1996. PMID: 8808170 Review.
Randomised clinical comparisons of depot goserelin with danazol indicate that goserelin is at least as effective as danazol and is better tolerated in the treatment of endometriosis. ...Goserelin is also an effective alternative to surgery in this patient gro …
Randomised clinical comparisons of depot goserelin with danazol indicate that goserelin is at least as effective as danazol an …
Goserelin: a review of its use in the treatment of early breast cancer in premenopausal and perimenopausal women.
Cheer SM, Plosker GL, Simpson D, Wagstaff AJ. Cheer SM, et al. Drugs. 2005;65(18):2639-55. doi: 10.2165/00003495-200565180-00011. Drugs. 2005. PMID: 16392882 Review.
Furthermore, the addition of goserelin to adjuvant chemotherapy appeared to offer an advantage over chemotherapy alone in younger patients. Fewer patients remained amenorrheic after goserelin therapy than after chemotherapy. Complete endocrine blockade provided by t …
Furthermore, the addition of goserelin to adjuvant chemotherapy appeared to offer an advantage over chemotherapy alone in younger pat …
Goserelin. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in prostate cancer.
Brogden RN, Faulds D. Brogden RN, et al. Drugs Aging. 1995 Apr;6(4):324-43. doi: 10.2165/00002512-199506040-00007. Drugs Aging. 1995. PMID: 7613021 Review.
Goserelin is administered subcutaneously as a biodegradable depot formulation incorporating 3.6mg of the drug, which is released continuously over 4 weeks. ...Goserelin is better tolerated than diethylstilbestrol and appears to have a more favourable effect on quali …
Goserelin is administered subcutaneously as a biodegradable depot formulation incorporating 3.6mg of the drug, which is released cont …
Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical use in sex hormone-related conditions.
Chrisp P, Goa KL. Chrisp P, et al. Drugs. 1991 Feb;41(2):254-88. doi: 10.2165/00003495-199141020-00008. Drugs. 1991. PMID: 1709853 Review.
The response to goserelin is more rapid than to diethylstilbestrol, and goserelin is better tolerated. ...Other gynaecological conditions reliant on the pituitary-gonadal axis also appear amenable to hormone manipulation with goserelin....
The response to goserelin is more rapid than to diethylstilbestrol, and goserelin is better tolerated. ...Other gynaecological …
Goserelin (Zoladex) in the treatment of fibroids.
West CP, Lumsden MA, Baird DT. West CP, et al. Br J Obstet Gynaecol. 1992 Feb;99 Suppl 7:27-30. doi: 10.1111/j.1471-0528.1992.tb13536.x. Br J Obstet Gynaecol. 1992. PMID: 1532507 Review. No abstract available.
Erythema nodosum caused by goserelin acetate sustained-release: Case report and literature review.
Meng F, Su R, Ling L, Yan W, Du S, Peng J, Liu W. Meng F, et al. Int J Rheum Dis. 2023 Oct;26(10):2055-2059. doi: 10.1111/1756-185X.14692. Epub 2023 Apr 28. Int J Rheum Dis. 2023. PMID: 37114900 Review.
Goserelin acetate is a gonadotropin-releasing hormone analog that is commonly used in patients with prostate cancer, endometriosis, and precocious puberty. ...In this paper, we have presented the case of erythema nodosum caused by goserelin acetate and a review of t …
Goserelin acetate is a gonadotropin-releasing hormone analog that is commonly used in patients with prostate cancer, endometriosis, a …
2,027 results